Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 5/20 | 0.46 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.41 |
| ▸ | PDE1A | P54750 | 5/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 5/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16366912 | 0.86 | PDE1B (0.46) | PDE1BADORA3MEN1KMT2A | |
| SCHEMBL3084224 | 0.84 | PDE1A (0.52) | PDE1BSLC16A1ADORA2AADORA2BADORA1 | |
| SCHEMBL2532754 | 0.84 | SLC16A1 (0.58) | PDE1BSLC16A1ADORA2AADORA2BADORA1 | |
| SCHEMBL7446626 | 0.83 | PDE1B (0.57) | PDE1BPDE1APDE1CPDE4AMEN1 | |
| SCHEMBL3389822 | 0.81 | PDE1B (0.43) | PDE1BSLC16A1ADORA2AADORA2BADORA1 | |
| Isobutyraldehyde SCHEMBL3661931 | 0.80 | PDE1A (0.48) | PDE1BSLC16A1ADORA2AADORA2BADORA1 | |
| Butanone SCHEMBL3661929 | 0.79 | PDE1A (0.46) | PDE1BSLC16A1ADORA2AADORA2BADORA1 | |
| SCHEMBL7000713 | 0.78 | MAPT (0.47) | PDE1BADORA1PDE1APDE1CADORA3 | |
| SCHEMBL18061465 | 0.77 | PDE1B (0.57) | PDE1BPDE1APDE1CPDE4APDE2A | |
| SCHEMBL5411368 | 0.77 | PDE1A (0.47) | PDE1BSLC16A1ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434730-B2 | PDE1 inhibitor compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20130338124-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2575817-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011153136-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338124-A1 | ORGANIC COMPOUNDS | OPRD1, PDE5A, PDE2A | PDE1B 93/4885SLC16A1 4849/4885ADORA2A 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.